Aptose Biosciences Inc.

Aptose Biosciences Inc.verified

APTO

Price:

$0.379

Market Cap:

$6.86M

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS); and HM43239 that is in Phase 1/2 clinical trial to treat patients with relapsed or refractory AML. The company also develops luxeptinib, which is in Phase 1a/b clinical trial for treating patients with relapsed or refractory B-cell malignancies, including chronic lymphocytic...[Read more]

Industry

Biotechnology

IPO Date

1992-03-16

Stock Exchange

NASDAQ

Ticker

APTO

The ROE as of September 2024 (TTM) for Aptose Biosciences Inc. (APTO) is -5693.38%

According to Aptose Biosciences Inc.’s latest financial reports and current stock price. The company's current ROE is -5693.38%. This represents a change of 255.80% compared to the average of -1600.16% of the last 4 quarters.

Aptose Biosciences Inc. (APTO) Historical ROE (quarterly & annually)

How has APTO ROE performed in the past?

The mean historical ROE of Aptose Biosciences Inc. over the last ten years is 95.06%. The current -5693.38% ROE has changed -6088.99% with respect to the historical average. Over the past ten years (40 quarters), APTO's ROE was at its highest in in the December 2023 quarter at 425.67%. The ROE was at its lowest in in the March 2024 quarter at -7012.33%.

Quarterly (TTM)
Annual

Average

95.06%

Median

-82.66%

Minimum

-205.01%

Maximum

1.81%

Aptose Biosciences Inc. (APTO) ROE by Quarter and Year

Discovering the peaks and valleys of Aptose Biosciences Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 170.00%

Maximum Annual ROE = 1.81%

Minimum Annual Increase = -1761.00%

Minimum Annual ROE = -205.01%

Quarterly (TTM)
Annual
YearROEChange
20231.81%-1761.00%
2022-108.78%23.73%
2021-87.91%91.08%
2020-46.01%68.16%
2019-27.36%-86.66%
2018-205.01%79.36%
2017-114.30%-39.62%
2016-189.30%144.52%
2015-77.41%170.00%
2014-0.05%-99.88%

Aptose Biosciences Inc. (APTO) Average ROE

How has APTO ROE performed in the past?

The current ROE of Aptose Biosciences Inc. (APTO) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

3-year avg

536.69%

5-year avg

307.34%

10-year avg

95.06%

Aptose Biosciences Inc. (APTO) ROE vs. Peers

How is APTO’s ROE compared to its peers?

Aptose Biosciences Inc.’s ROE is less than CytomX Therapeutics, Inc. (-27.44%), less than Instil Bio, Inc. (-55.57%), less than Neoleukin Therapeutics, Inc. (-47.64%), less than Spero Therapeutics, Inc. (20.70%), greater than Assembly Biosciences, Inc. (-121.55%), greater than Fortress Biotech, Inc. (-226.63%), less than Mustang Bio, Inc. (1.40%), less than Achilles Therapeutics plc (-47.36%), greater than Fortress Biotech, Inc. (-226.63%), greater than Gain Therapeutics, Inc. (-214.20%), greater than TFF Pharmaceuticals, Inc. (-225.16%), less than aTyr Pharma, Inc. (-56.83%), greater than IN8bio, Inc. (-173.12%), less than Lantern Pharma Inc. (-46.39%), greater than Affimed N.V. (-155.57%), greater than Leap Therapeutics, Inc. (-98.01%), greater than Adaptimmune Therapeutics plc (-117.47%), less than Corvus Pharmaceuticals, Inc. (-53.99%), less than Longboard Pharmaceuticals, Inc. (-36.93%), greater than TRACON Pharmaceuticals, Inc. (-237.65%), less than Oncternal Therapeutics, Inc. (120.03%), less than Aeglea BioTherapeutics, Inc. (197.28%),

Build a custom stock screener for Aptose Biosciences Inc. (APTO) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Aptose Biosciences Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Aptose Biosciences Inc. (APTO) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Aptose Biosciences Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the ROE?

How can you use the ROE?

What is Aptose Biosciences Inc.'s ROE?

How is the ROE calculated for Aptose Biosciences Inc. (APTO)?

What is the highest ROE for Aptose Biosciences Inc. (APTO)?

What is the 3-year average ROE for Aptose Biosciences Inc. (APTO)?

What is the 5-year average ROE for Aptose Biosciences Inc. (APTO)?

How does the current ROE for Aptose Biosciences Inc. (APTO) compare to its historical average?